Gain Therapeutics, Inc. (GANX) — Financial statements
Income statement, balance sheet, and cash flow for Gain Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00↓100.0% | 0.06↓58.4% | 0.13↓1.0% | 0.13 | |
| Cost of Revenue | 0.09 | 0.00 | 0.00↓100.0% | 8↑15.1% | 7 | |
| Gross Profit | -0.09 | 0.00↓100.0% | 0.06↑100.7% | -8↓15.4% | -7 | |
| Operating Expenses | ||||||
| R&D Expenses | 10↓5.4% | 11↓6.3% | 12↑36.2% | 8↑15.1% | 7 | |
| General & Administrative Expenses | 8↓11.1% | 10↓11.4% | 11↑14.2% | 9↑38.4% | 7 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00↓100.0% | 0.24↑2007.7% | 0.01 | |
| SG&A Expenses | 8↓11.1% | 10↓11.4% | 11↑11.4% | 10↑41.6% | 7 | |
| Other Expenses | -0.09 | 0.00 | 0.00↑100.0% | -8↓14.7% | -7 | |
| Operating Expenses | 19↓8.5% | 20↓8.8% | 22↑130.8% | 10↑42.2% | 7 | |
| Total Costs & Expenses | 19↓8.1% | 20↓8.8% | 22↑24.6% | 18↑28.3% | 14 | |
| Operating Results | ||||||
| Operating Income | -19↑8.1% | -20↑8.5% | -22↓25.2% | -18↓28.6% | -14 | |
| Depreciation & Amortization | 0.09↑11.9% | 0.08↑0.6% | 0.08↑213.8% | 0.03↑72.0% | 0.02 | |
| EBITDA | -19↑8.1% | -20↑8.6% | -22↓24.8% | -18↓28.5% | -14 | |
| EBIT | -19↑8.1% | -20↑8.5% | -22↓25.1% | -18↓28.5% | -14 | |
| Interest & Other Income | ||||||
| Net Interest Income | 0.24↓31.6% | 0.36↓27.7% | 0.49↑31.7% | 0.38↑2904.1% | 0.01 | |
| Interest Income | 0.24↓31.6% | 0.36↓27.7% | 0.49↑31.7% | 0.38↑2904.1% | 0.01 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | 0.00 | 0.00 | 0.00↓100.0% | 0.01↓9.9% | 0.01 | |
| Other Income / Expenses | -0.59↓223.7% | 0.48↑633.9% | 0.06↓76.8% | 0.28↑562.2% | -0.06 | |
| Income Before Tax | -19↑2.9% | -20↑10.4% | -22↓26.8% | -17↓26.0% | -14 | |
| Income Tax Expense | 0.86↑60.4% | 0.54↑577.2% | 0.08↓14.7% | 0.09↑2219.8% | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -20↑1.2% | -20↑8.3% | -22↓26.6% | -18↓26.6% | -14 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -20↑1.2% | -20↑8.3% | -22↓26.6% | -18↓26.6% | -14 | |
| Bottom-Line Net Income | -20↑1.2% | -20↑8.3% | -22↓26.6% | -18↓26.6% | -14 | |
| EPS (Basic) | -0.61↑31.5% | -0.89↑48.0% | -1.71↓15.5% | -1.48↓8.0% | -1.37 | |
| EPS (Diluted) | -0.61↑31.5% | -0.89↑48.0% | -1.71↓15.5% | -1.48↓8.0% | -1.37 | |
| Weighted Average Shares | 33↑44.1% | 23↑75.9% | 13↑9.5% | 12↑16.9% | 10 | |
| Weighted Average Diluted Shares | 33↑44.1% | 23↑75.9% | 13↑9.5% | 12↑16.9% | 10 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.